Eagle Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-676,136
| Closed | -$55.5M | – | 535 |
|
|
2024
Q2 | $55.5M | Sell |
676,136
-36,393
| -5% | -$3.03M | 0.3% | 116 |
|
|
2024
Q1 | $62.1M | Buy |
712,529
+276,250
| +63% | +$24.7M | 0.31% | 115 |
|
|
2023
Q4 | $42.1M | Sell |
436,279
-1,812
| -0.4% | -$160K | 0.23% | 134 |
|
|
2023
Q3 | $38.8M | Sell |
438,091
-19
| -0% | -$1.69K | 0.23% | 133 |
|
|
2023
Q2 | $38M | Buy |
+438,110
| New | +$41.2M | 0.21% | 135 |
|
|
2021
Q2 | – | Sell |
-564,702
| Closed | -$44M | – | 602 |
|
|
2021
Q1 | $44M | Buy |
564,702
+31,326
| +6% | +$2.56M | 0.19% | 167 |
|
|
2020
Q4 | $46.8M | Sell |
533,376
-43,340
| -8% | -$3.44M | 0.26% | 140 |
|
|
2020
Q3 | $43.8M | Sell |
576,716
-2,083
| -0.4% | -$211K | 0.23% | 157 |
|
|
2020
Q2 | $70.7M | Buy |
578,799
+153,457
| +36% | +$15.3M | 0.4% | 101 |
|
|
2020
Q1 | $35.9M | Buy |
+425,342
| New | +$36.6M | 0.22% | 159 |
|
|
2018
Q2 | – | Sell |
-398,436
| Closed | -$32.3M | – | 624 |
|
|
2018
Q1 | $32.3M | Buy |
398,436
+25,459
| +7% | +$2.18M | 0.18% | 189 |
|
|
2017
Q4 | $33.2M | Buy |
372,977
+52,913
| +17% | +$4.6M | 0.18% | 191 |
|
|
2017
Q3 | $30M | Buy |
320,064
+13,711
| +4% | +$1.21M | 0.17% | 201 |
|
|
2017
Q2 | $27.8M | Buy |
306,353
+54,675
| +22% | +$4.97M | 0.17% | 201 |
|
|
2017
Q1 | $22.1M | Sell |
251,678
-3,544
| -1% | -$315K | 0.14% | 216 |
|
|
2016
Q4 | $21.1M | Buy |
255,222
+81,878
| +47% | +$7.04M | 0.14% | 209 |
|
|
2016
Q3 | $16M | Sell |
173,344
-2,140
| -1% | -$202K | 0.11% | 250 |
|
|
2016
Q2 | $13.7M | Buy |
175,484
+2,861
| +2% | +$243K | 0.09% | 277 |
|
|
2016
Q1 | $14.2M | Sell |
172,623
-1,067
| -0.6% | -$86.8K | 0.1% | 277 |
|
|
2015
Q4 | $18.2M | Buy |
173,690
+21,749
| +14% | +$2.27M | 0.12% | 233 |
|
|
2015
Q3 | $16M | Buy |
151,941
+14,787
| +11% | +$1.98M | 0.11% | 242 |
|
|
2015
Q2 | $18.8M | Buy |
137,154
+10,611
| +8% | +$1.31M | 0.11% | 238 |
|
|
2015
Q1 | $15.8M | Buy |
126,543
+3,701
| +3% | +$392K | 0.09% | 265 |
|
|
2014
Q4 | $11.1M | Sell |
122,842
-1,305
| -1% | -$109K | 0.06% | 315 |
|
|
2014
Q3 | $8.96M | Buy |
124,147
+1,987
| +2% | +$131K | 0.05% | 338 |
|
|
2014
Q2 | $7.6M | Sell |
122,160
-3,265
| -3% | -$197K | 0.04% | 382 |
|
|
2014
Q1 | $8.55M | Sell |
125,425
-575
| -0.5% | -$42.4K | 0.05% | 375 |
|
|
2013
Q4 | $8.86M | Sell |
126,000
-71,964
| -36% | -$4.89M | 0.05% | 329 |
|
|
2013
Q3 | $14.7M | Buy |
197,964
+4,028
| +2% | +$268K | 0.07% | 298 |
|
|
2013
Q2 | $10.8M | Buy |
+193,936
| New | +$12.1M | 0.07% | 333 |
|
Other funds holding BMRN
EIM
Eagle Asset Management's BMRN Position: Q3 2024 in Review
Eagle Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 676,136 shares — an estimated $55.5M sold.
Eagle Asset Management first reported a position in BMRN in Q2 2013 and held it in 30 quarters. The position peaked at $70.7M in Q2 2020. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.
- Eagle Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
- Eagle Asset Management sold 676,136 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $55.5M.
- Eagle Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Eagle Asset Management's BioMarin Pharmaceuticals position peaked at $70.7M in Q2 2020.
- 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.
Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.